This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Altria Group has been evolving with the changing industry dynamics. Given the rising health consciousness and stern government regulations to discourage smoking, this tobacco behemoth has been moving beyond traditional cigarettes and expanding in the smokeless category. We note that revenues from the oral product category have been steadily rising on the back of growing popularity for reduced risk products. In this respect, Altria is gaining from the sale of IQOS in United States, through its licensing deal with Phillip Morris. Further, Altria’s investment in Cronos Group highlights its focus on exploring the cannabis market.
Inside the Q1 Earnings Strength of Staples ETFs and Q2 View
by Sanghamitra Saha
Staples stocks had a decent Q1 earnings season but will see negative currency translations in Q2. Plus, not all players in the sector are immune to coronavirus-led lockdowns.
Cronos (CRON) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Investors will focus on regular top and bottom-line numbers along with its pipeline progress, when Cronos (CRON) reports Q1 results.
Altria's (MO) Q1 Earnings Top Estimates, Guidance Withdrawn
by Zacks Equity Research
Altria's (MO) first-quarter 2020 results reflect growth in oral tobacco products and smokeable segments. Management withdraws 2020 earnings guidance due to coronavirus.
Altria (MO) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Altria (MO) delivered earnings and revenue surprises of 12.37% and 9.23%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Why Altria Group (MO) Might Surprise This Earnings Season
by Zacks Equity Research
Altria Group (MO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Here's What You Must Note Ahead of Altria's (MO) Q1 Earnings
by Zacks Equity Research
Altria's (MO) first-quarter 2020 performance is likely to reflect gains from pricing and strength in Smokeless products.
Altria (MO) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Altria (MO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Altria (MO) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Altria (MO) closed at $40.39 in the latest trading session, marking a -1.27% move from the prior day.
BTI vs. MO: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
BTI vs. MO: Which Stock Is the Better Value Option?
Altria (MO) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Altria (MO) closed the most recent trading day at $37.14, moving -0.72% from the previous trading session.
Top ETF Stories of First Quarter
by Sanghamitra Saha
Inside the ETF stories that hit the headlines in the first quarter.
Altria (MO) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Altria (MO) closed the most recent trading day at $37.31, moving +1.83% from the previous trading session.
Philip Morris Suspends Operations at MTB Due to Coronavirus
by Zacks Equity Research
Philip Morris (PM) will suspend all operations at Philip Morris Manufacturing & Technology Bologna S.p.A., Italy, for a week.
Altria (MO) Stock Moves -1.75%: What You Should Know
by Zacks Equity Research
Altria (MO) closed at $43.16 in the latest trading session, marking a -1.75% move from the prior day.
Why Is Altria (MO) Down 15.9% Since Last Earnings Report?
by Zacks Equity Research
Altria (MO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Altria (MO) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Altria (MO) closed at $40.37 in the latest trading session, marking a +0.16% move from the prior day.
Philip Morris Focuses on RRPs Amid Low Cigarette Volumes
by Zacks Equity Research
Phillip Morris (PM) has been expanding in the RRP category. Also, the company's pricing strategy is providing cushion amid receding cigarette volumes.
Altria's (MO) Q4 Earnings Beat Estimates, Revenues Down Y/Y
by Zacks Equity Research
Altria's (MO) fourth-quarter 2019 results reflect gains from strong pricing. Revenues improve in the smokeless products unit but decline in the smokeable products unit.
Altria (MO) Q4 Earnings Top Estimates
by Zacks Equity Research
Altria (MO) delivered earnings and revenue surprises of 0.99% and -1.94%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Altria (MO) Stock Moves -0.57%: What You Should Know
by Zacks Equity Research
Altria (MO) closed at $50.27 in the latest trading session, marking a -0.57% move from the prior day.
Altria (MO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Altria (MO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's What You Should Note Ahead of Altria (MO) Q4 Earnings
by Zacks Equity Research
Altria's (MO) fourth-quarter 2019 results are likely to reflect gains from pricing and RRPs amid soft cigarette volumes.
Can Coca-Cola (KO) Retain Its Positive Earnings Trend in Q4?
by Zacks Equity Research
Coca-Cola's (KO) fourth-quarter 2019 results are likely to reflect benefits from its innovation efforts, product investments, strength across regions, and robust price/mix and volume.
Here's All You Must Note Ahead of McCormick (MKC) Q4 Earnings
by Zacks Equity Research
McCormick's (MKC) fourth-quarter fiscal 2019 results are likely to reflect gains from innovation and savings from the CCI program. However, volatile currency movements are concerning.
Archer Daniels (ADM) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Softness in Ag Services and Oilseeds, and Carbohydrate Solutions units is likely to have negatively impacted Archer Daniels' (ADM) Q4 performance. Its growth efforts are expected to have benefited.